Skip Navigation
Skip to contents

ICDM 2023

D--540 TODAY.
2025-04-11
Menu Close

Program details

Home

Program
Program details

Menu View

Joint sessions
JS1 KDA-SHVM joint session Advances in diabetes-related cardiovascular and cerebrovascular research Chair(s): Jaetaek Kim, Eun Seok Kang
Thursday 19 October, 16:50~18:10
Room 1 (3F)
In this session, we bring you three interconnected presentations that shed light on promising treatments and underlying mechanisms. The first presentation, "Novel Therapeutic Targets for Diabetic Cardiomyopathy," focuses on emerging treatments for diastolic dysfunction in diabetes. These innovative approaches aim to enhance the quality of life for affected individuals. Our second presentation, "Pancreatic Amylin and Diabetic Cerebrovascular Complications," explores amylin's impact beyond the pancreas, particularly in cerebrovascular issues. We discuss recent findings and their implications for diabetic patients. Lastly, "HEG1's Role in Endothelial Function and Atherosclerosis" offers fresh insights into vascular health. Discoveries surrounding HEG1 as a blood flow-sensitive molecule open new avenues in preventing atherosclerosis, a common diabetic complication. Together, we aim to advance our understanding and improve care for individuals facing diabetes-related cardiovascular and cerebrovascular challenges.
John Ussher JS1-1
John Ussher University of Alberta, Canada
New therapeutic targets for alleviating diastolic dysfunction in diabetic cardiomyopathy
Florin Despa JS1-2
Florin Despa The University of Kentucky, USA
Aβ efflux impairment and inflammation linked to cerebrovascular accumulation of amyloid-forming amylin secreted from pancreas
Hanjoong Jo JS1-3
Hanjoong Jo Emory University, USA
Role of flow-sensitive HEG1 in endothelial function and protection against atherosclerosis
Panel discussion
  • Hyoung Kyu Kim JS1-Panel 1
    Hyoung Kyu Kim Inje University, Korea
  • Shin Ae Kang JS1-Panel 2
    Shin Ae Kang Yonsei University, Korea
  • Yong Seek Park JS1-Panel 3
    Yong Seek Park Kyung Hee University, Korea
JS2 KDA-KSGCR joint session Unveiling silent (hidden) connections between pancreatic cancer and diabetes Chair(s): Kyu Chang Won, Seungmin Bang
Friday 20 October, 09:00~10:40
Room 5 (2F)
Metabolic abnormalities and pancreatic cancer interact with each other. Metabolic syndrome and obesity affect the risk of pancreatic cancer. Conversely, the development of pancreatic cancer induces changes in metabolic profiles, such as an increase in blood sugar levels. This joint session with the Korean Society of Gastrointestinal Cancer Research (KSGCR) will shed light on the dynamics between metabolic dysfunction and pancreatic cancer and on practical animal models to investigate this area.
Gromski, Mark A JS2-1
Mark A. Gromski Indiana University, USA
Obesity and diabetes as two intersecting risk factors for pancreas cancer
JS2-2
Minyoung Lee Yonsei University, Korea
Rapid deterioration of new-onset diabetes and risk of pancreatic cancer
JS2-3
Jung Yong Hong Sungkyunkwan University, Korea
Changes in metabolic syndrome status are associated with altered risk of pancreatic cancer: a nationwide cohort study
JS2-4
Sang Hoon Lee Konkuk University, Korea
Experimental models for the connection between pancreatic cancer and diabetes
Panel discussion
  • Seung Jin Han JS2-Panel 1
    Seung Jin Han Ajou University, Korea
  • JS2-Panel 2
    Shin Ae Kang Yonsei University, Korea
  • JS2-Panel 3
    Dong Uk Kim Pusan National University, Korea
  • JS2-Panel 4
    Min-Kyu Jung Kyungpook National University, Korea
JS3 KDA-KSHF joint session Unveiling the connection between heart failure and metabolic diseases Chair(s): Kyu Chang Won, Seok Min Kang
Saturday 21 October, 09:00~10:40
Room 1 (3F)
The relationship between diabetes, obesity and heart failure is multifaceted. Those conditions are influenced by shared risk factors and can exacerbate each other's effects. This joint session with the Korean Society of Heart Failure (KSHF) will provide updated information regarding optimal patient care strategies in diabetes and heart failure. Additionally, the associations between glucose variability and acute heart failure, the relationship between NAFLD, obesity and heart failure will be highlighted.
Junghyun Noh JS3-1
Junghyun Noh Inje University, Korea
Evaluation and management of patients with diabetes and heart failure: a Korean Diabetes Association and Korean Society of Heart Failure consensus statement
Jaewon Oh JS3-2
Jaewon Oh Yonsei University, Korea
In-hospital glycemic variability and all-cause mortality among patients hospitalized for acute heart failure
Marat Fudim JS3-3
Marat Fudim Duke Clinical Research Institute, USA
Intersection of heart failure and NAFLD
Masaaki Konishi JS3-4
Masaaki Konishi Yokohama City University, Japan
Obesity and heart failure
JS4 KDA-IAS joint session Insights for recent management of diabetes reducing cardiovascular risks and FH treatment based on precision medicine Chair(s): Sunghee Choi, Brian Tomlinson
Saturday 21 October, 09:00~11:00
Room 5 (2F)
We will have a joint session with international atherosclerosis society (IAS). In this session, we will discuss many important topics of anti-diabetic treatment and cardiovascular diseases. The last speaker will talk the recent update of familial hypercholestrolemia treatment. Firstly, KDA guideline committee will introduce update KDA guidelines focused on SGLT 2 inhibitor and GLP1 therapy. Second speaker will discuss SGLT2 inhibitor and CVOTs. GLP 1 based therapy will be updated and its effect on CVDs will be discussed. For the special lecture from IAS side, recent knowledge of FH risk stratification and treatment will be delivered.
JS4-1
Jong Han Choi Konkuk University, Korea
Recent updates in diabetes guidelines by the KDA: overview of cardiovascular and renal management with SGLT-2 inhibitors and GLP-1RAs
JS4-2
Brian Tomlinson Macau University of Science and Technology, Macau SAR, China
Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
JS4-3
Chang Hee Jung University of Ulsan, Korea
GLP 1 based therapy including its effect on cardiovascular risk and lipid profiles
JS4-4
Raul D. Santos University of Sao Paulo, Brazil
Precision medicine for atherosclerotic cardiovascular disease risk stratification and therapy in Familial Hypercholesterolemia
KDA 대한당뇨병학회Korean Diabetes Association
  • (04146) 101-2104, Lotte Castle President, 109 Mapo-gu, Seoul, Korea
  • Tel: +82-2-714-9064 | E-mail: diabetes@kams.or.kr
  • Business Registration Number: 106-82-31108 | Name of Representative: Kyu-Chang Won
Congress Secretariat (Planbear)
  • #1101, 220, Gonghang-daero, Gangseo-gu, Seoul(07806), Republic of Korea
  • Tel: +82-2-6734-1011/1012/1013  E-mail: icdm@diabetes.or.kr

copyright© By Korean Diabetes Association.
All rights reserved.
Businuess Registration Number: 106-82-31108
Name of Representative : Kyu-Chang Won